Age modulates the relationship between platelet-to-lymphocyte ratio and coronary artery disease

Issada Trakarnwijitr1, Bobby Li1, Heath Adams2

  • 1St Vincent's Hospital Melbourne, Department of Medicine, The University of Melbourne, Melbourne, Australia; Monash Health, Monash Medical Centre, Melbourne, Australia.

Insights

The platelet-to-lymphocyte ratio (PLR) shows an age-dependent association with coronary artery disease (CAD). High PLR indicates increased CAD risk in older patients but decreased risk in younger patients.

Area of Science:

  • Cardiology
  • Biomarkers
  • Inflammation

Background:

  • Atherosclerosis pathogenesis involves thrombocytosis and inflammation.
  • Platelet-to-lymphocyte ratio (PLR) is a novel biomarker for cardiovascular disease (CVD).
  • The association between PLR and coronary artery disease (CAD) requires further investigation, particularly concerning age-related effects.

Purpose of the Study:

  • To determine the correlation between PLR and CAD in high-risk patients.
  • To investigate whether age modifies the relationship between PLR and CAD.

Main Methods:

  • 822 patients undergoing coronary angiography were analyzed.
  • Patients were stratified into premature CAD (age<55) and non-premature CAD (age≥55) groups.
  • Multivariate logistic regression adjusted for traditional cardiovascular risk factors.

Main Results:

  • Univariate analysis showed high PLR negatively correlated with premature CAD.
  • After adjustment, high PLR was associated with increased CAD in older patients (OR 2.22) and decreased CAD in younger patients (OR 0.31).
  • The association between high PLR and CAD in older patients reached statistical significance (P=0.004).

Conclusions:

  • PLR demonstrates an age-related effect on CAD correlation.
  • High PLR is an independent marker of CAD in older high-risk individuals.
  • PLR can serve as an accessible and inexpensive tool for identifying patients at high risk for CAD.
Abstract

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
810
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.3K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
770
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
512
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
474